XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jul. 02, 2023
Jun. 30, 2024
Jul. 02, 2023
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     $ 1,988  
Provision/(credit) [2] $ 1,104 $ 138 1,114 $ 94
Utilization and other [3]     (703)  
Balance, ending [4] 2,399   2,399  
Other Current Liabilities [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning     1,300  
Balance, ending 1,000   1,000  
Other Noncurrent Liabilities [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning     663  
Balance, ending 1,400   1,400  
Employee Termination Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     1,978  
Provision/(credit)     984  
Utilization and other [3]     (592)  
Balance, ending [4] 2,370   2,370  
Asset Impairment Charges [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     0  
Provision/(credit)     66  
Utilization and other [3]     (66)  
Balance, ending [4] 0   0  
Exit Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     11  
Provision/(credit)     63  
Utilization and other [3]     (45)  
Balance, ending [4] $ 29   $ 29  
[1] Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.1 billion for both the three and six months ended June 30, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program for both periods presented and credits of $113 million for the three months and $199 million for the six months ended June 30, 2024 for our Realigning our Cost Base Program). Amounts associated with our Biopharma segment for the three and six months ended July 2, 2023 were not material.
[3] Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
[4] Included in Other current liabilities ($1.0 billion) and Other noncurrent liabilities ($1.4 billion).